Clinical trial
Chloroquine to Treat People With Metabolic Syndrome Aim2 (ARCH-MS)
NCT00455325 · Washington University School of Medicine, Other · Completed
Key facts
| NCT number | NCT00455325 |
|---|---|
| Title | Chloroquine to Treat People With Metabolic Syndrome Aim2 (ARCH-MS) |
| Official title | Genotoxic Stress, Atherosclerosis, and Metabolic Syndrome-AIM 2 |
| Acronym | ARCH-MS |
| Lead sponsor | Washington University School of Medicine, Other |
| Collaborators | National Heart, Lung, and Blood Institute (NHLBI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Metabolic Syndrome X, Overweight, Hypertension, Dyslipidemias, Prediabetic State |
| Intervention type | Drug |
| Interventions | Placebo Comparator: First Intervention (3 weeks), Active Comparator: Second Intervention (3 weeks), Active Comparator: Third Intervention (3 weeks), Active Comparator: Fourth Intervention (3 weeks) |
| Enrollment | 35 |
| Start date | Sep 1, 2004 |
| Primary completion | Jun 1, 2010 |
| Completion | Mar 1, 2012 |
| First posted | Apr 3, 2007 |
| Last update posted | May 10, 2022 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: